H.C. Wainwright analyst Raghuram Selvaraju initiated coverage of Climb Bio (CLYM) with a Buy rating and $9 price target The firm views Climb Bio as a “disruptive innovator” in the field of B cell-mediated autoimmune diseases. Comparable valuations “hint at considerable upside potential” for the shares, the analyst tells investors in a research note.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CLYM: